Norgine Ventures
VC Fund
Uxbridge, United Kingdom
Norgine Ventures is a VC fund in Uxbridge focused on Health Care and Medical Device. Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. Norgine Ventures is backed by Norgine, a fully integrated, private,European healthcare company with over 110 years of experience in the pharma space.Norgine Ventures has full access to Norgine’s technical capabilities for evaluating investment opportunities, although the business is aimed at achieving a financial return rather than funding opportunities of strategic interest to Norgine.To date, Norgine Ventures has invested in a number of businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle, both in Europe and in the US.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries Norgine Ventures invests in
Health CareMedical DeviceBiotechnologyMedicalManufacturing
Stages Norgine Ventures invests in
Funding RoundDebt FinancingVenture - Series UnknownSeries ASeries B
Countries Norgine Ventures invests in
United KingdomFranceThe NetherlandsGermanyUnited States
Round sizes
Debt Financing $2.6M–$16M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Debt Financing
- $2.6M–$16M
Investment Focus
Industry
- Health Care 16 (64%)
- Medical Device 15 (60%)
- Biotechnology 8 (32%)
- Medical 7 (28%)
- Manufacturing 6 (24%)
Stage
- Funding Round 9 (36%)
- Debt Financing 5 (20%)
- Venture - Series Unknown 3 (12%)
- Series A 2 (8%)
- Series B 2 (8%)
Country
- United Kingdom 5 (20%)
- France 4 (16%)
- The Netherlands 3 (12%)
- Germany 2 (8%)
- United States 2 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jörg Plessl
Director EU Affiliates, Regulatory Affairs at Germany
|
Director EU Affiliates, Regulatory Affairs at Germany | Total investments: 0 | Find email | |
Julien Michaux
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Moritz Reuter
Investment Associate
|
Investment Associate | Total investments: 0 | Find email | |
Peter Stein
Founder
|
Founder | Total investments: 11 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Magentiq Eye Ltd
|
Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. | Series A / Jul 30, 2025 | |
Lunaphore
|
Lunaphore Technologies S.A. is a Swiss company born with the vision of accelerating cancer research by bringing the field of spatial biology into mainstream laboratories. Lunaphore has developed its innovative spatial biology solutions based on an award-winning technology called FFeX (Fast Fluidic Exchange). Lunaphore has been recognized as one ofthe most innovative companies internationally. | $10.9M / Debt Financing / Mar 23, 2023 | |
Sirius Medical
|
Sirius Medical helps improve healthcare for cancer patients by developing medical devices that aid in surgical treatment. Their objective is to create intuitive and accurate gadgets that allow surgeons and radiologists to provide the finest treatment. Sirius Perception uses audio and visual feedback to provide real-time, directional advice forpinpointing tumors | $12.9M / Series B / Mar 21, 2023 | |
|
Magentiq Eye Ltd
|
Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. | $600K / Convertible Note / Aug 16, 2022 | |
Impress
|
Impress – is European leading digital orthodontic DSO of new generationWe have a defensible model with the personal touch of an in-house orthodontist, true clinical expertise, and engaging directly with consumersImpress was founded in 2019 in Barcelona with the idea of combining the best of orthodontic tradition with the most innovativetechnology in the sector. From the very beginning the vision of the Impress founders was to introduce a different business model with a strong focus on medical experience and digitalization. The company is transforming the oral healthcare industry by developing its own chain of orthodontic clinics, which are characterized by their disruptive design and modern patient experience. The founders decided to build a medical company with the personal touch of in-house orthodontists, face-to-face care, and unique clinical expertise, where the proper implementation of business processes and digitalization are at the core.In less than 2 years, Impress has managed to position itself as the European leader in the orthodontic sector, has treated more than 22.000 smiles and already has a presence in more than 80 European cities. Its innovation and quality have earned it recognition from Sifted as one of the fastest growing HealthTech companies in Europe in 2020. | $125M / Series B / Jul 11, 2022 | |
Inovus Medical
|
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical techniques with Pyxus. The only take home simulator that includes lap appendectomy and cholecystectomy training models. | $7M / Venture - Series Unknown / May 17, 2022 | |
|
Magentiq Eye Ltd
|
Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. | $1.8M / Convertible Note / Jul 31, 2021 | |
Alesi Surgical
|
Alesi Surgical was founded in 2009 to develop and commercialise products that improve the safety, efficacy and outcomes of surgical procedures. The company is a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experiencedsurgeons, surgical trainers and trainees, which allows it to identify issues in procedures and design devices to address these issues. | $12.8M / Venture - Series Unknown / Jul 20, 2021 | |
ImaginAb
|
ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized forclinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics. | $12.8M / Venture - Series Unknown / Jun 03, 2021 | |
PathoQuest
|
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurancemanagers/production managers.PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection.PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies. | $8.8M / Sep 06, 2019 | |
| See all 25 investments → | |||
Co-Investors
Claret Capital Partners
2 deals together
Adage Capital Management
1 deal together
aMoon Fund
1 deal together
BOM Brabant Ventures
1 deal together
Charles River Laboratories International
1 deal together
Curie Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Climate VC Funds
33,091 investors
FAQ
What does Norgine Ventures invest in?
Norgine Ventures invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Funding Round and Debt Financing stage. Most of the 25 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Norgine Ventures's check size?
Norgine Ventures typically joins rounds of $2.6M–$16M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Norgine Ventures participates in.
How do I contact Norgine Ventures?
Public channels for Norgine Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Norgine Ventures?
The team at Norgine Ventures includes Jörg Plessl (Director EU Affiliates, Regulatory Affairs at Germany), Julien Michaux (Managing Director) and Moritz Reuter (Investment Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
